Published on 17/11/2025

Defining Retention Periods for Different Document and Data Types

Retention periods for documents and data generated during clinical trials are dictated by regulatory requirements and institutional policies. These periods ensure compliance, facilitate audits, protect institutional interests, and preserve the integrity of trial data. This guide will offer a systematic approach to establishing retention periods for various document and data types, focusing on the requirements in the US, UK, and EU.

Understanding Clinical Trial Documentation

Clinical trials generate a wide array of documents. Each document type may have different retention requirements based on its purpose, the type of information it contains, and prevailing regulatory guidelines. Documents can be categorized into the following groups:

Regulatory Documents: Documents necessary for gaining regulatory approval, including protocols, informed consent forms, and IND applications.
Study Data: All data collected during the trial, including clinical trial results, laboratory data, and patient-reported outcomes.
Monitoring Documents: Records generated by monitors during sponsor oversight or regulatory agency inspections.
Quality Assurance Documents: Procedures and evaluations conducted as part of quality assurance processes.

A clear understanding of these documents is crucial when deciding on retention policies, particularly in regulated environments such as those dictated by the ICH-GCP guidelines. For instance, pivotal trials, like the vx 880 clinical trial, require meticulous documentation and retention to support claims made for drug efficacy and safety.

Regulatory Considerations for Document Retention

In navigating the complexities of clinical trial document retention, professionals must be aware of guidelines set forth by various health authorities, including the FDA, EMA, and MHRA. Below are details regarding their requirements:

FDA Requirements

The FDA mandates that clinical trial sponsors retain essential documents for an extended period. According to 21 CFR 312.62, the following documents must be retained for at least two years after the end of the clinical trial:

Records of the clinical investigation.
Case histories for each subject.
Data from informed consent forms and adverse event reports.

However, if the investigational product has an active marketing application, records should be kept for a significantly longer duration. This means sponsors must consider how their documentation and data management practices correspond with these FDA mandates.

EMA Guidelines

For studies conducted under the auspices of the European Medicines Agency (EMA), legislation typically requires that essential documents are archived for at least 25 years or as stipulated in the Marketing Authorization application. Specifically, documents like clinical trial applications and subject consent forms must be kept for this duration post completion of the trial. Compliance with this guideline ensures that all data can be retrieved if auditing or further investigatory requirements arise.

MHRA Stipulations

The UK Medicines and Healthcare products Regulatory Agency (MHRA) also has similar retention requirements to ensure accountability. Critical documents must typically be retained for a minimum of 5 years after the end of a clinical trial. However, for commercially sponsored trials, it is vital to reference the specific protocol since additional requirements may exist.

Document Type Retention Standards

Based on the regulatory guidelines, the retention period for each type of clinical trial documentation can vary widely. Below we delineate the recommended retention times for core document categories:

Essential Clinical Trial Documents

Essential documents like trial protocols, case report forms (CRFs), and investigator brochures are foundational to any trial. For these documents, the recommended retention period generally extends for the duration specified below:

Clinical Trial Protocol: 25 years post final approval.
Case Report Forms and Source Documents: 15 years after the completion of the study or marketing authorization.
Informed Consent Forms: 10 years post-study completion.

Study Data

The retention of study data is of utmost importance in preserving the integrity and validity of trial results. Here are the recommended retention times for different data types:

Raw Data: 15 years after the conclusion of the study.
Data Analysis Reports: 25 years post-publication.
Statistical Analysis Plans: 25 years.

Clearly documenting these data retention policies is critical for compliance across various jurisdictions, and professionals can use resources such as the ICH guidelines for detailed compliance recommendations.

Institutional Policies on Document Retention

In addition to regulatory requirements, each research institution often has its own policies regarding the retention of clinical trial documents. These policies may exceed baseline regulations and are essential for ensuring institutional compliance and governance.

Creating Internal Guidelines

To establish effective retention policies, institutions should create a comprehensive internal guideline that aligns with both regulatory and institutional standards. Key components of these guidelines should include:

Clear Definitions: Defining each document type and its purpose within clinical trials.
Retention Period: Stipulating how long each type of document should be maintained.
Archiving Protocols: Outlining how documents will be stored, either electronically or physically.
Destruction Procedures: Detailing how and when documents will be securely destroyed once they are no longer needed.

Training and Compliance

Educating clinical research staff on the importance of document retention and the specific guidelines they are required to follow is key. Regular training sessions can help mitigate risks associated with data loss and support compliance throughout the lifecycle of clinical research. Establishing ongoing dialogues and check-ins with the compliance and legal teams can be immensely beneficial.

Digital Solutions for Document Management

Modern clinical trial operations can significantly benefit from utilizing electronic document management systems (EDMS). These systems can automate many aspects of retention management while enhancing data integrity and compliance monitoring. By adopting such technology, organizations can:

Streamline Document Retrieval: Simplifying access to documents upon request and during audits.
Maintain Version Control: Ensuring that all documentation is up-to-date and eliminating confusion.
Ensure Secure Archiving: Establishing secure digital storage that complies with global standards.

Choosing a capable EDMS can also introduce efficiencies into the clinical trial process by reducing administrative burdens on clinical research staff. For instance, systems compatible with tools for project management, such as those utilized in IBMs clinical trials, greatly enhance collaboration and retention management.

Conclusion: Ensuring Compliance and Best Practices

Document retention in clinical trials is critical not only for compliance but also for the integrity of clinical research. By establishing robust policies that align with regulatory guidance, conducting regular training, and leveraging technology, clinical research professionals in the US, UK, and EU can ensure that their document management processes enhance accountability and support the future of clinical development.

Utilizing the structured approach described in this guide will enable your organization to navigate the complexities of document retention effectively while also integrating best practices to maximize compliance across all phases of the clinical trial.